Diabetes, Vol 35, Issue 11 1268-1277, Copyright © 1986 by American Diabetes Association

ARTICLES

Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy

MR Taskinen, WF Beltz, I Harper, RM Fields, G Schonfeld, SM Grundy and BV Howard

To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apolipoprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 +/- 4 vs. 35 +/- 6 g/day, P = .10) but not of VLDL apoB (1595 +/- 106 vs. 1597 +/- 164 mg/day, NS); production of VLDL TG declined to control levels (33 +/- 4 g/day, P less than .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 +/- .9 vs. 13.1 +/- .9 pools/day, P less than .05) and VLDL apoB (5.6 +/- .4 vs. 7.5 +/- 0.7, P less than .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 +/- 1.5, P less than .05, and 6.7 +/- .4, P less than .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 +/- .09 vs. .92 +/- .25 mumol X g-1 X h-1, P less than .01), which increased during therapy (to .61 +/- .17, P less than .05). Hepatic lipase also decreased significantly after therapy (27.4 +/- 3.6 to 26.4 +/- 3.2, P less than .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 +/- .6 vs. 11.7 +/- .8, P less than .01); this ratio fell during therapy (to 12.5 +/- .8, P less than .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. A. Deeg, J. B. Buse, R. B. Goldberg, D. M. Kendall, A. J. Zagar, S. J. Jacober, M. A. Khan, A. T. Perez, M. H. Tan, and on behalf of the GLAI Study Investigators Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care, October 1, 2007; 30(10): 2458 - 2464. [Abstract] [Full Text] [PDF]

				E. J. Parks and M. K. Hellerstein Thematic review series: Patient-Oriented Research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques J. Lipid Res., August 1, 2006; 47(8): 1651 - 1660. [Abstract] [Full Text] [PDF]

				M. Adiels, J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S.-O. Olofsson, C. Packard, and M.-R. Taskinen Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1697 - 1703. [Abstract] [Full Text] [PDF]

				K. G. Tolman, V. Fonseca, M. H. Tan, and A. Dalpiaz Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus Ann Intern Med, December 21, 2004; 141(12): 946 - 956. [Abstract] [Full Text] [PDF]

				L. R. Tannock, K. L. Olin, P. H. R. Barrett, T. N. Wight, and A. Chait Triglyceride-Rich Lipoproteins from Subjects with Type 2 Diabetes Do Not Demonstrate Increased Binding to Biglycan, a Vascular Proteoglycan J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 35 - 40. [Abstract] [Full Text] [PDF]

				C. Maugeais, U. J. F. Tietge, K. Tsukamoto, J. M. Glick, and D. J. Rader Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice J. Lipid Res., October 1, 2000; 41(10): 1673 - 1679. [Abstract] [Full Text]

				J. Bülow, L. Simonsen, D. Wiggins, S. M. Humphreys, K. N. Frayn, D. Powell, and G. F. Gibbons Co-ordination of hepatic and adipose tissue lipid metabolism after oral glucose J. Lipid Res., November 1, 1999; 40(11): 2034 - 2043. [Abstract] [Full Text]

				S. Lemieux, B. W. Patterson, A. Carpentier, G. F. Lewis, and G. Steiner A stable isotope method using a [2H5]glycerol bolus to measure very low density lipoprotein triglyceride kinetics in humans J. Lipid Res., November 1, 1999; 40(11): 2111 - 2117. [Abstract] [Full Text]

				F. Diraison and M. Beylot Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E321 - E327. [Abstract] [Full Text] [PDF]

				P. J. Coussons, C. S. Bourgeois, D. Wiggins, and G. F. Gibbons Selective Recruitment of ApoB-48 for the Assembly of VLDL in Rat Triacylglycerol-Enriched Hepatocytes Arterioscler. Thromb. Vasc. Biol., July 1, 1996; 16(7): 889 - 897. [Abstract] [Full Text]